Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Two high-priced JAK inhibitors (Incyte’s Jakafi and BMS’s Inrebic) are the only FDA-approved drugs to treat MF, leaving hematologists with limited options. Treatment costs are set to increase with expected approval of new therapies, including Sierra Oncology’s momelotinib and CTI BioPharma’s pacritinib, in the near future. We explore reimbursement of approved MF therapies in commercial and Medicare plans, MCO coverage of off-label therapies for MF, and the impact of reimbursement policies on hematologists’ use of MF therapies. In addition, this report assesses how U.S. hematologists and payers will react to new emerging therapies entering the market and how payer policies will affect hematologists’ adoption.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Release date: September 2021.
Geography: United States.
Primary research: Survey of 100 U.S. hematologists and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
Fingertip formulary: Formulary coverage for MF therapies by commercial plans covering 162.7 million lives nationally and Medicare Part D plans covering up to 36.2 million lives.
Key drugs covered: Jakafi, Inrebic, Epogen, Aranesp.
Key analysis provided:
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.